Microcap Ledger Q32 Bio Inc. $QTTB
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Fiscal year end
- December 31
- Shares outstanding
- 29,769,466 [10-Q 2026-08-05]
What the company doesAI summary of filing
Q32 Bio is a clinical-stage biotechnology company developing biologics to treat autoimmune and inflammatory diseases. The company's lead candidate is bempikibart (ADX-914), a fully human monoclonal antibody that blocks IL-7 and TSLP signaling, currently in Phase 2a trials for alopecia areata and atopic dermatitis. The company has no approved products or product revenue and is pre-revenue, relying on development funding and investor capital. Q32 also retains a tissue-targeted complement inhibitor platform including ADX-096, though it sold substantially all ADX-097 assets to Akebia Therapeutics in November 2025. [10-K 2026-03-10]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$16.55M | −$9.42M | $106.27M | [10-Q 2026-08-05] |
| FY ended Dec 2025 | $53.74M | $29.80M | −$33.54M | $48.30M | [10-K 2026-03-10] |
| FY ended Dec 2024 | $0.00 | −$47.70M | −$67.72M | $77.97M | [10-K 2026-03-10] |
- Quarterly cash burn
- −$4.71M
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 12,180,701 | [10-Q 2024-11-07] |
| 2025-03-03 | 12,197,615 | [10-K 2025-03-11] |
| 2025-05-01 | 12,197,615 | [10-Q 2025-05-08] |
| 2025-08-01 | 12,197,615 | [10-Q 2025-08-06] |
| 2025-11-01 | 12,304,352 | [10-Q 2025-11-13] |
| 2026-03-01 | 14,629,463 | [10-K 2026-03-10] |
| 2026-05-01 | 16,956,415 | [10-Q 2026-05-05] |
| 2026-08-03 | 29,769,466 | [10-Q 2026-08-05] |
- Shelf registration
- S-3 filed 2026-07-17; declared effective 2026-07-28 [S-3 2026-07-17]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-05-23. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-05-23 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-23] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-25 | Morrison Jodie Pope | sell | 9,845 | $16.56 | [4 2026-08-27] |
| 2026-08-25 | Kalowski Lee | sell | 3,972 | $16.56 | [4 2026-08-27] |
| 2026-08-25 | Violette Shelia M. | sell | 2,798 | $16.56 | [4 2026-08-27] |
| 2026-07-16 | Violette Shelia M. | grant | 37,500 | — | [4 2026-07-20] |
| 2026-07-16 | Morrison Jodie Pope | grant | 132,000 | — | [4 2026-07-20] |
| 2026-07-16 | Kalowski Lee | grant | 53,250 | — | [4 2026-07-20] |
| 2026-06-30 | Manke Isaac | exercise | 53,521 | $2.80 | [4 2026-07-02] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-09-30 | 8-K | Regulation FD disclosure; Other events |
| 2026-09-14 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Results of operations |
| 2026-07-31 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-28 | 424B3 | Prospectus or prospectus supplement |
| 2026-07-20 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-07-17 | S-3 | Registration statement |
| 2026-07-15 | 8-K | Material agreement entered |
Alerts for $QTTB
Email me when Q32 Bio Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.